Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Immunol. 2021 Nov 24;208(1):16–26. doi: 10.4049/jimmunol.2100643

Figure 5. DR1-CII CAR T cells inhibit the development reduce the severity of autoimmune arthritis in B6.DR1 mice.

Figure 5.

B6.DR1 mice were immunized with CII/CFA and treated on days 7, 14 and 21 following disease induction with 2 × 106 DR1-CII CAR T cells, or non-transduced (NT) CD8+ T cells, or left untreated. Mice were observed 3 times per week for the presence of arthritis in fore and hind limbs. A. Mice receiving DR1-CII CAR T cells had a statistically significantly lower incidence of disease than both control groups (★ indicates p < 0.05 by Fisher Exact test, p values ranged from 0.04 to 0.0015), and had a later onset. B. In mice that developed arthritis, the mean severity of the disease was decreased in comparison to control groups (NT CAR T cells and untreated). Data indicate mean severity score of the sum of all 4 limbs of only mice that developed disease. Error bars indicate standard error of the mean (SEM), and ★ indicates statistical significance (p ≤ 0.05 by student’s t-test). The last day of CAR cell treatment corresponds to the first day of disease scoring. Data are a compilation of 3 independent experiments, n = 15 for the untreated group, n = 29 for the NT treated group, and n = 30 for the CAR T cell treated group.